Klotho Neurosciences, Inc

Klotho Neurosciences, Inc. develops medicines for cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy candidates are KLTO-101 for the treatment or prevention of Alzheimer's disease and KLTO-202 for the treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. It is based in Omaha, Nebraska.